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Introduction
Prostate cancer is the most common cancer in middle-
aged and elderly men after lung cancer with the prevalence 
of 25.3 per 10,000. The previous studies have shown that one 
man in six will suffer from this cancer during his lifetime. Ge-
netic, hormonal, and environmental factors are known to be 
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Abstract: Prostate cancer is the most common cancer type in men and is the second cause of death, due to cancer, in patients 
over 50, after lung cancer. Prostate specific antigen (PSA) is a widely used tumor marker for prostate cancer. Recently, PSA is 
discovered in non-prostatic cancer tissues in men and women raising doubts about its specificity for prostatic tissues. PSA exists 
in low serum level in healthy men and in higher levels in many prostate disorders, including prostatitis and prostate cancer. 
Thus, a supplementary tumor marker is needed to accurately diagnose the cancer and to observe the patient after treatment. 
Recently, soluble human leukocyte antigen-G (sHLA-G) has been introduced as a new tumor marker for different cancer types, 
including colorectal, breast, lung, and ovary. The present descriptive-experimental study was carried out including patients with 
malignant prostate tumor, patients with benign prostate tumor, and a group of health men as the control group, as judged by 
an oncologist as well as a pathologist. After sterile blood sampling, sHLA-G was measured by enzyme-linked immunosorbent 
assay in each group. The data was then analyzed using one-way ANOVA. P≤0.05 was considered as statistically significant. The 
results showed that the mean of sHLA-G level was high in patients. Also, it was found that there was a significant difference in 
sHLA serum level between the three groups. The data revealed that sHLA-G can be a novel supplementary tumor marker in 
addition to PSA to diagnose prostate cancer.
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involved in the incidence of this cancer. It is most prevalent 
in the Northern Europe and Africa, and the least incidence is 
reported in the Asian population [1, 2].
Screening, diagnosis, and treatment in the early stages of 
prostate cancer can improve the patients' life expectancy and 
quality of life and decrease morbidity and mortality [3]. Digi-
tal rectal examination and serum prostate specific antigen 
(PSA) measurement are the main diagnostic methods [4].
PSA is a proteolytic enzyme released by normal and neo-
pla stic prostate cells. Any damage to prostate, including 
hyper plasia, adenocarcinoma, cystoscopy, prostatitis, and 
senility, has been reported to increase the serum level of this 
antigen; however, this antigen is widely used to diagnose 
prostate cancer [5-7].
This specific antigen is in a higher level in patients with 
prostate cancer although it does not necessarily indicate af-
fliction to it as high level of PSA is also observed in many 
men with benign hyperplasia of prostate and urinary tract 
infections. To confidently diagnose prostate cancer, PSA 
measurement is followed by further tests including magnetic 
resonance imaging, computed tomography, ultrasound, and 
prostate biopsy. However, about 25% of prostate cancer is not 
diagnosed after first biopsy [8].
The previous studies have shown that despite the negative 
result of biopsy, PSA level increases, but in a few percentages 
of gland lesions, the level of PSA does not increase.
Therefore, considering the restriction and the low diagnos-
tic accuracy of screening methods, finding a reliable method 
of diagnosis is significant [9]. Recently, human leukocyte 
antigen-G (HLA-G) has been introduced as a tumor marker 
for breast cancer, lung cancer, skin cancer, ovarian cancer, and 
gastrointestinal cancer [10]. It is shown that the evaluation of 
HLA-G level in serum or plasma can increase specificity of 
diagnosis [11-13].
The present study is an attempt to evaluate the level of this 
tumor marker in comparison with the pathological findings 
in patients suffering from prostate cancer and to assess its ef-
ficiency as a new biomarker for screening purposes.
Materials and Methods
The present descriptive-experimental study was carried 
out in Nowshahr Medical Diagnostic Institute (Feb 2014–
Jan 2015). First, among the patients who had referred to the 
laboratory, those with prostate cancer who met the inclusion 
criteria were selected and informed about the study. Prior to 
biopsy procedure, all the participants wrote and signed the 
consent form and their familial history was elicited.
Inclusion criteria were patients with benign or acute pros-
tate cancer, approval of the cancer stage by an oncologist and 
a pathologist, and no history of other diseases. Patients whose 
cancer stage was unknown were excluded from the study.
Participants were divided into three groups: group 1 in-
cluded 26 patients with acute prostate cancer; group 2 in-
cluded 26 patients with benign prostate cancer; and group 3, 
com prised of 26 healthy participants. Two milliliters of blood 
was sampled from each participant. After separating serum 
in sterilized condition, the levels of biomarkers were mea-
sured in the three groups using Human AHLA-G ELISA Kit 
(Elabscience-Biotechnology, Wuhan, China). The data was 
analyzed by one-way analysis of variance (ANOVA) with sig-
nificance set at P<0.05.
Results
The statistical analyses revealed that the levels of PSA in 
malignant group, benign group, and control group were 3.45, 
2.88, and 2.31, respectively, showing no statistically significant 
different between the groups (P<0.05) (Fig. 1). The highest 
level of PSA was found in the malignant group. The results of 
measuring HLA-G level were 1.68, 1.59, and 0.83 in malig-
nant tumor group, benign tumor group, and control group, 
respectively, demonstrating a statically significant different 
between the three groups (P<0.05) (Fig. 2). The highest level 
of HLA-G was found in the group with malignancy. Also, 
when the mean of the serum level of PSA was compared with 
that of the serum level of HLA-G, no significant difference 
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Fig. 1. Mean and standard deviation of prostate specific antigen (PSA) 
level in malignant group, benign group, and control group (P<0.01).
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was observed between the three groups (P<0.05) (Fig. 3).
Discussion
The aim of the present study was to evaluate serum level 
of HLA-G as an efficient tumor marker in screening and di-
agnosis of patients with prostate cancer and also to compare 
HLA-G and PSA in terms of their biomarker role. The serum 
level of PSA was abnormal in patients who suffered from 
prostate cancer, but no significant difference was observed be-
tween the malignant group and benign group with regard to 
the level of this biomarker. Moreover, the mean of the serum 
level of HLA-G was found to be high in the three groups. The 
results of the statistical analyses showed that there is a signifi-
cant difference between the three groups of study concerning 
the serum level of HLA-G with the highest level belonging to 
the malignant tumor group and the least level to the control 
group; therefore, it can be stated that there is a positive cor-
relation between the serum level of HLA-G and the stage of 
cancer. Evaluation of PSA level is routinely used in laborato-
ries for screening prostate cancer where increase in the serum 
level of this antigen is interpreted as increase in the severity of 
the disease, yet according to our findings, there is no correla-
tion between the disease, cancer stage, and the serum level of 
PSA.
HLA-G is one of the molecules of MHC I that plays the 
roles of immunosuppression and regulatory of natural killer 
cell and dendritic cell T-cell [10]. Previous studies have re-
ported on the clinical linkage between an increase in expres-
sion of HLA-G in diseases such as cancer, viral infection, 
pregnancy, organ transplants, autoimmune disease, and 
inflammations. HLA-G expression were found, for the first 
time, in trophoblastic cell in chorion playing fundamental 
roles in protecting fetus against mother's immune system, 
survival of the fetus, and early stages of placenta angiogenesis 
[13]. Also, HLA-G has been detected in people receiving al-
lograft and tumor progression in several cancers [14]. Similar 
to our findings, Wang et al. [15] has reported that there is 
positive a correlation between expression of HLA-G and size 
of glioma tumor. In another study, Guo et al. [16], after evalu-
ation of the expression of HLA-E or HLA-G in patients with 
colorectal cancer, concluded that there is a direct relationship 
between HLA-G or HLA-E and metastasis rate and mortality.
In 2006, expression of HLA-G1, -G2, -G5, and -G6 were 
evaluated in normal prostate tissue, prostate hyperplasia, and 
prostate adenocarcinoma by Langat et al. [17]. They reported 
that HLA-G5 exists in prostate tissue and it increases in tissue 
secretion of prostate adenocarcinoma.
According to findings of the present study, the evaluation 
of serum level of HLA-G can be used as a novel and an easy 
method for screening, diagnosis, and staging of prostate can-
cer, as early diagnosis of prostate cancer can decrease morbid-
ity and mortality and increase life expectancy in the patients.
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Fig. 2. Mean and standard deviation of human leukocyte antigen-G 
(HLA-G) level in malignant group, benign group, and control group 
(*P<0.05).
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Fig. 3. The comparison between the serum level of prostate specific 
antigen (PSA) and the serum level of soluble human leukocyte 
antigen-G (sHLA-G) (*P<0.05).
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